Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13151939 | 0.91 | GPR119 (0.43) | GPR119CYP2C9PTGS2PTGS1SMN1; SMN2 | |
| SCHEMBL10133868 | 0.90 | GPR119 (0.43) | GPR119CYP2C9PTGS2PTGS1SMN1; SMN2 | |
| SCHEMBL15381349 | 0.90 | GPR119 (0.46) | GPR119CYP2C9PTGS2PTGS1SMN1; SMN2 | |
| SCHEMBL10116433 | 0.89 | GPR119 (0.48) | GPR119CYP2C9PTGS2PTGS1SMN1; SMN2 | |
| SCHEMBL10105824 | 0.89 | GPR119 (0.48) | GPR119CYP2C9PTGS2PTGS1SMN1; SMN2 | |
| SCHEMBL10120668 | 0.88 | GPR119 (0.46) | GPR119CYP2C9PTGS2PTGS1SMN1; SMN2 | |
| SCHEMBL10116389 | 0.87 | GPR119 (0.46) | GPR119CYP2C9PTGS2PTGS1SMN1; SMN2 | |
| SCHEMBL15381350 | 0.80 | GPR119 (0.53) | GPR119CYP2C9PTGS2PTGS1TRPA1 | |
| SCHEMBL10134280 | 0.78 | PTGS2 (0.45) | GPR119CYP2C9PTGS2PTGS1TRPA1 | |
| SCHEMBL10120874 | 0.78 | GPR119 (0.56) | GPR119CYP2C9ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580807-B2 | Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, BDKRB2, GLP1R | GPR119 1/4885CYP2C9 999/4885PTGS2 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.